ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 22, 2009 | $135,478 | Replaced |
| 1st Quarter - Amendment | Aug 6, 2009 | $66,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Proposed changes to the Medicare Part D prescripion drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| RYAN DAY | — |
| LAUREN LEA FULLER | Chief Investigative Counsel, Sen. Finance Cmte. |
| WILLIAM HERMELIN | — |
Health Issues HCR
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| RYAN DAY | — |
| LAUREN LEA FULLER | Chief Investigative Counsel, Sen. Finance Cmte. |
| WILLIAM HERMELIN | — |
Labor Issues/Antitrust/Workplace LBR
Legislation granting independent pharmacists collective bargaining rights.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| RYAN DAY | — |
| LAUREN LEA FULLER | Chief Investigative Counsel, Sen. Finance Cmte. |
| WILLIAM HERMELIN | — |
Pharmacy PHA
Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| RYAN DAY | — |
| LAUREN LEA FULLER | Chief Investigative Counsel, Sen. Finance Cmte. |
| WILLIAM HERMELIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.